Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Nicole Concin; Ioana Braicu; Pierre Combe; Isabelle Laure Ray-Coquard; Florence Joly; Philipp Harter; Pauline Wimberger; Jean-Pierre Lotz; Atanas Ignatov; Barbara Schmalfeldt; Els van Nieuwenhuysen; Silvia Darb-Esfahani; Marina Riedmann; Alain G Zeimet; Sven Mahner; Eric Pujade-Lauraine; Christian Marth; Regina Berger; Jalid Sehouli; Ignace Vergote

doi:10.1200/jco.2018.36.15_suppl.5567

Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5567 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5567-5567 ◽

Cited By ~ 2

Author(s):

Nicole Concin ◽

Ioana Braicu ◽

Pierre Combe ◽

Isabelle Laure Ray-Coquard ◽

Florence Joly ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase Ii ◽

Hsp90 Inhibitor ◽

Weekly Paclitaxel ◽

High Grade ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Platinum Resistant

Download Full-text

Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5578 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5578-5578

Author(s):

Isabelle Ray-Coquard ◽

Ioana Braicu ◽

Regina Berger ◽

Sven Mahner ◽

Jalid Sehouli ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Hsp90 Inhibitor ◽

Weekly Paclitaxel ◽

High Grade ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Platinum Resistant

Download Full-text

Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e17038 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e17038-e17038 ◽

Cited By ~ 1

Author(s):

Nicole Concin ◽

Ioana Braicu ◽

Regina Berger ◽

Sven Mahner ◽

Jalid Sehouli ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Hsp90 Inhibitor ◽

Weekly Paclitaxel ◽

High Grade ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Platinum Resistant

Download Full-text

840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.979 ◽

2020 ◽

Vol 31 ◽

pp. S630

Author(s):

L. Xia ◽

Q. Zhou ◽

Y. Zhang ◽

Y. Gao ◽

W. Hu ◽

...

Keyword(s):

Cervical Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Cervical Cancer ◽

Open Label ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

Platinum Resistant

Download Full-text

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.10.001 ◽

2018 ◽

Vol 151 (3) ◽

pp. 422-427 ◽

Cited By ~ 7

Author(s):

Bradley J. Monk ◽

James T. Kauderer ◽

Katherine M. Moxley ◽

Albert J. Bonebrake ◽

Summer B. Dewdney ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant

Download Full-text

Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium

Frontiers in Oncology ◽

10.3389/fonc.2019.00832 ◽

2019 ◽

Vol 9 ◽

Cited By ~ 2

Author(s):

Isabelle Ray-Coquard ◽

Ioana Braicu ◽

Regina Berger ◽

Sven Mahner ◽

Jalid Sehouli ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Epithelial Ovarian Cancer ◽

Hsp90 Inhibitor ◽

Weekly Paclitaxel ◽

High Grade ◽

Multicenter Phase ◽

Platinum Resistant

Download Full-text

A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Annals of Oncology ◽

10.1093/annonc/mdx372.061 ◽

2017 ◽

Vol 28 ◽

pp. v352-v353

Author(s):

K.N. Moore ◽

K.A. Cadoo ◽

S. Chambers ◽

S. Ghamande ◽

G. Konecny ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Primary Peritoneal Cancer ◽

Multicentre Phase ◽

Peritoneal Cancer ◽

Platinum Resistant

Download Full-text

Saracatinib (AZD0530) plus weekly paclitaxel in platinum resistant ovarian, fallopian tube or primary peritoneal cancer

http://isrctn.org/> ◽

10.1186/isrctn32163062 ◽

2012 ◽

Author(s):

Lee Webber

Keyword(s):

Fallopian Tube ◽

Weekly Paclitaxel ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Platinum Resistant

Download Full-text

5002 ORAL Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71174-6 ◽

2007 ◽

Vol 5 (4) ◽

pp. 311-312

Author(s):

S. Makhija ◽

D. Glenn ◽

F. Ueland ◽

D. Dizon ◽

V. Paton ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Double Blind Trial ◽

Double Blind ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Blind Trial ◽

Platinum Resistant

Download Full-text

Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5580 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5580-5580

Author(s):

John Ben Liao ◽

Ron E. Swensen ◽

Jessica Reichow ◽

Kelsie J Ovenell ◽

Jennifer Childs ◽

...

Keyword(s):

Immune Responses ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Immune Modulator ◽

Gm Csf ◽

Platinum Resistant

Download Full-text

Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.06.032 ◽

2021 ◽

Author(s):

Floor J. Backes ◽

Lai Wei ◽

Min Chen ◽

Kasey Hill ◽

Kyle Dzwigalski ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Weekly Paclitaxel ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer

Download Full-text